Exosome transfer of nucleic acids to cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 60/797,149, filed May 3, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,629,929 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence UsedRemaining | Lonza Sales AG | In force | High confidence | ||
| US 9,889,210 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence | Lonza Sales AG | In force | High confidence | ||
| US 10,695,443 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence | Lonza Sales AG | In force | High confidence | ||
| US 9,085,778 | Exosome transfer of nucleic acids to cells In force (reinstated) · High confidence | Lonza Sales AG | In force (reinstated) | High confidence | ||
| Application 15/857,539 | Exosome Transfer of Nucleic Acids to Cells Abandoned Abandoned Dec 17, 2018 | Lonza Sales AG | Abandoned | Abandoned Dec 17, 2018 | ||
| Application 16/905,719 | Exosome Transfer of Nucleic Acids to Cells Abandoned Abandoned Feb 23, 2024 | Lonza Sales AG | Abandoned | Abandoned Feb 23, 2024 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Lonza Sales AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.